January 15, 2013

In the article, Pharma’s Stake in CER, adapted from the book Healthcare at a Turning Point: A Roadmap for Change, NAI Managing Partner, Michael N. Abrams, M.A., spotlights comparative effectiveness research (CER) as a new reality for the pharmaceutical industry that demands radical revision of its business model. Michael previews the implications of increased CER application, making the financial prospects of new products a function of the economic and clinical value they deliver.

See the article, published in Pharmaceutical Commerce as Pharma’s Stake in CER, January 2013.